Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 15/20 | 0.55 |
| ▸ | MMEL1 | Q495T6 | 5/20 | 0.50 |
| ▸ | ACE | P12821 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20578496 | 1.00 | MME (0.55) | MMEMMEL1ACEKDM4EALDH1A1 | |
| SCHEMBL16930454 | 1.00 | MME (0.55) | MMEMMEL1ACEKDM4EALDH1A1 | |
| SCHEMBL18874681 | 0.93 | MMEL1 (0.49) | MMEMMEL1ACE | |
| SCHEMBL16941027 | 0.91 | MME (0.49) | MMEMMEL1ACE | |
| SCHEMBL16941514 | 0.91 | MME (0.49) | MMEMMEL1ACE | |
| SCHEMBL20306304 | 0.90 | MMEL1 (0.47) | MMEMMEL1ACE | |
| SCHEMBL11969730 | 0.90 | MME (0.54) | MMEMMEL1ACECTSL | |
| SCHEMBL18411073 | 0.90 | MME (0.54) | MMEMMEL1ACECTSL | |
| SCHEMBL11970064 | 0.90 | MME (0.54) | MMEMMEL1ACECTSL | |
| SCHEMBL11969971 | 0.89 | MME (0.70) | MMEMMEL1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783507-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170137388-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137388-A1 | NEPRILYSIN INHIBITORS | MME, REN, AGTR1 | MME 1/4885MMEL1 200/4885ACE 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.